DRD5 and neoplasm: For instance, Wu and colleagues have shown that the pharmacologic stimulation of type I dopamine receptors (including DRD1 and DRD5) reduces the suppressive function of MDSC, thus enhancing the potency of the T-cell-mediated anti-tumour response [56].